VanEck US Equity Buffer ETF - October

30.84

+0.09270.30%

Volume:6K

Turnover:175.95K

Market Cap:1.23M

PE:- -

High:30.89

Open:30.86

Low:30.84

Close:30.75

52wk High:32.83

52wk Low:30.51

Shares:40.00K

Float Shares:40.00K

Volume Ratio:0.53

T/O Rate:14.25%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

GlobeNewswire

·

Oct 02

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/OCT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCT\",,,,,undefined,":{"symbol":"OCT","market":"US","secType":"STK","nameCN":"VanEck US Equity Buffer ETF - October","latestPrice":30.8402,"timestamp":1791576000000,"preClose":30.7475,"halted":0,"volume":5698,"delay":0,"changeRate":0.003014879258476321,"floatShares":40000,"shares":40000,"eps":0,"marketStatus":"Market Closed","change":0.0927,"latestTime":"10-09 16:00:00 EDT","open":30.86,"high":30.89,"low":30.8402,"amount":175949,"amplitude":0.00162,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":30.7475,"volumeRatio":0.5261602732505247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCT\",,,,,undefined,":{"symbol":"OCT","floatShares":40000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5261602732505247,"shares":40000,"dividePrice":0,"high":30.89,"amplitude":0.00162,"preClose":30.7475,"low":30.8402,"week52Low":30.5094,"pbRate":"--","week52High":32.83,"institutionHeld":0,"latestPrice":30.8402,"eps":0,"divideRate":0,"volume":5698,"delay":0,"ttmEps":0,"open":30.86,"prevYearClose":30.68,"prevWeekClose":30.6507,"prevMonthClose":30.68,"prevQuarterClose":30.68,"fiveDayClose":30.6507},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OCT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672112037","title":"Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2672112037","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672112037?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:00","pubTimestamp":1790942400,"startTime":"0","endTime":"0","summary":"First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373778/0/en/surrozen-announces-fda-clearance-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDL","CNAV","XNTK","AMDW","BK4529","LU1861559042.SGD","TRFK","WUGI","AIQ","LEGR","CHAT","TTEQ","AMDC","SOXY","AMD","AIS","PSI","WISE","USXF","BK4532","SMH","IE00BMPRXQ63.HKD","LABU","GAMR","LU2461242641.AUD","OCT","AMDS","AMDD","FTXL","SAMD0main","AMDY","CHPS","FAI","LU1861220033.SGD","AMDU","IETC","SMHX","ILDR","SOXX","TEK","AMDG","DAMD","BK4575","QQQA","ARTY","AMYY","BAI","AMUU","LU2458330169.SGD","IND"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/OCT\",params:#limit:6,delay:false,,,undefined,":[]}}